« Patients with polycythemia vera (PV) require life-long treatment to prevent thromboembolic events and minimize the risk of progression. Ropeginterferon alpha-2b (BESREMi®; hereafter ropeg) may ultimately modify the natural history of PV by selectively targeting the malignant clone. In the PROUD-PV/CONTINUATION-PV studies, long-term treatment with ropeg was compared with standard cytoreductive therapy regarding thromboembolic and other adverse events as well as evolution of hematologic and molecular parameters over five years. »
Long-Term Use of Besremi in Polycythemia Vera: 5... - MPN Voice
Long-Term Use of Besremi in Polycythemia Vera: 5-Year Results from a Randomized Controlled Study and Its Extension
Written by
Manouche
To view profiles and participate in discussions please or .
14 Replies
•
Thank you. Very encouraging 😊
Thanks for posting. This is encouraging. I wonder if those of us on Pegasys will be able to switch over?
More promising data for the use of Besremi. Besremi was mentioned in the recent MPN Advocacy Intl. Webinar with hope that it will be much easier for PV patients to access the drug once it is FDA approved for PV. Hopefully it will be so.
Anyone know when it’s coming to the USA?
Is there any country that Besremi is already approved???
• in reply toAneliv9
Germany approved it and it has been in use since late 2019. I believe it has been approved by the EU as a whole and also some Asian countries
Many thanks for posting this link Manouche.
Thank you for sharing
Not what you're looking for?
You may also like...
ASH 2019 | Ropeg in polycythemia vera: long-term PROUD-PV and CONTI-PV results
https://www.vjhemonc.com/video/elvsbiyxlco-ropeg-in-polycythemia-vera-long-term-proud-pv-and-conti-p
BESREMI ACHIEVES PATIENT-SPECIFIC TREATMENT GOALS IN POLYCYTHEMIA VERA: FINAL RESULTS FROM THE PROUD-PV/CONTINUATION-PV STUDIES
« No phlebotomies were required to maintain hematocrit <45% in the 6th year of treatment in 81.4%...
Updated Phase 2 Data Supporting Long-Term Efficacy of Rusfertide in Polycythemia Vera
Summary of Results:
Therapeutic phlebotomies were essentially eliminated and a target hematocrit...
Polycythemia vera and essential thrombocythemia of intermediate-age: A real-life, multicenter analysis of first-line treatment approach
»In regard to PV, the decision to introduce cytoreduction may be more understandable than in ET....
Ruxolitinib Versus Best Available Therapy for Polycythemia Vera Intolerant or Resistant to Hydroxycarbamide in a Randomized Trial
« Patients with PV often have high JAK2 V 617F VAF (>50%) because of the emergence of a dominant...